Biotechnology innovation often demands a blend of scientific breakthroughs and forward-thinking financial strategies. In the intense competition to develop new medicines, companies need both robust intellectual property rights and innovative funding approaches that avoid constant share dilution to stay competitive. This is becoming increasingly important for biotech companies that are exploring unique treasury management and asset strategies, including the incorporation of digital assets.
Examples of Crypto-Enabled Treasury Strategies
One of the most well-known instances of a company using cryptocurrency as a core treasury asset is Strategy Inc. (Nasdaq: MSTR), formerly known as MicroStrategy. The company has strategically adopted Bitcoin as its primary treasury reserve. In May of 2025, Strategy Inc. announced it had generated approximately $427 million through ATM offerings (at-the-market offerings of common and preferred stock) and used these funds to purchase an additional 4,020 Bitcoins, bringing their total holdings to 580,250 BTC.
Their approach is straightforward: raise capital through equity or preferred stock, and then convert it into cryptocurrency, while continuing their main business operations in intelligence and analytics.
BitMine Immersion Technologies (NYSE American: BMNR) has followed a similar path, building a substantial Ethereum treasury for a publicly traded company. As of mid-September 2025, BMNR holds over 2.15 million ETH, along with Bitcoin and significant cash reserves. Their total crypto and cash holdings are estimated to be in the multi-billion-dollar range, with recent disclosures valuing them around US$10.8 billion, depending on Ethereum’s price.
BMNR describes its strategy as a “crypto + cash + moonshots” portfolio, where “moonshots” represent smaller investments in equity or tokens, aimed at capturing potential gains beyond their core ETH and BTC holdings.
Hoth Therapeutics (NASDAQ: HOTH), a biotech company in the clinical trial stage, also adopted a cryptocurrency treasury reserve strategy in late 2024. Their board approved allocating up to $1 million in Bitcoin as a treasury reserve asset, citing the increasing institutional acceptance, the rise of ETFs, and the potential of cryptocurrency to hedge against inflation.
While smaller in scale than Strategy Inc. or BMNR, this move is significant for a biotech company that is still pre-commercial in its core therapeutic areas. It demonstrates a growing willingness among biotech companies to combine drug development with alternative financial hedging and treasury diversification strategies.
Propanc Biopharma’s Dual Strategy: Patents and Crypto
Propanc Biopharma, Inc. (Nasdaq: PPCB) has recently achieved a significant milestone in its intellectual property strategy. On September 17, 2025, Propanc was granted a patent certificate from the US Patent & Trademark Office (USPTO) for its “proenzyme composition” patent, which specifically protects the planned clinical dose of its leading drug candidate, PRP.
This is their fourth US patent. Propanc’s overall IP portfolio now includes 90 patents filed across major global jurisdictions, all related to the use of PRP in treating solid tumors.
This patent is particularly important as Propanc prepares to initiate a Phase 1B, First-In-Human (FIH) study involving patients with advanced cancer. The “future clinical dose” clause secures exclusivity for the dosage level that Propanc intends to use in human trials, protecting a clinically relevant formulation. The patent’s international reach is also crucial, as the same proenzyme composition patent has been approved in Europe, Japan, and throughout Southeast Asia.
Digital Asset Diversification Strategy
In parallel with its advancements in patent protection, Propanc is also implementing a digital asset diversification strategy to enhance its financial stability. This strategy is designed to reduce reliance on frequent fundraising and to support operations during the pre-revenue, early clinical stage.
In early September 2025, Propanc revealed its plans to acquire $100 million worth of Ethereum over the next year. The rationale is that holding Ethereum could provide financial flexibility through potential appreciation, increased liquidity, and alternative financial leverage, all while not interfering with their core biotech mission. The cryptocurrency acts as a financial tool to accelerate the drug development process and achieve key R&D milestones.
Scientific and Market Potential
Propanc’s therapeutic approach is unique: PRP utilizes pancreatic proenzymes to target cancer stem cells and modulate EMT (epithelial-to-mesenchymal transition), encouraging malignant cells to revert to a less aggressive state instead of directly killing them. This strategy is designed to be relatively non-toxic and aims to prevent the metastasis and recurrence of solid tumors, including pancreatic, ovarian, and colorectal cancers.
The global market for metastatic cancer treatment is projected to reach $111.2 billion by 2027, highlighting the significant potential if PRP proves successful in human trials.
A Combined Financing Approach
By combining a stronger IP portfolio with a cryptocurrency treasury strategy, Propanc is aiming to establish a capital structure that extends its financial resources. The newly granted patents protect future revenue and licensing opportunities. Simultaneously, the Ethereum acquisition plan could enable Propanc to generate or preserve cash without solely depending on equity dilution or traditional biotech funding, which are often expensive and time-consuming.
The plan to initiate Phase 1B trials next year depends not only on the science but also on having sufficient capital to execute the trials. Propanc has stated that they are “pursuing every avenue for raising sufficient capital and employing a digital asset diversification strategy to ensure optimal cash flow as we advance PRP towards important clinical milestones.”
Key Takeaways and What to Monitor
- IP as a Competitive Advantage: The “clinical dose” patent transforms a previously vague area (the dosage used in humans) into a more concrete and defensible asset, which is vital for partnering, licensing, and attracting major pharmaceutical companies.
- Cryptocurrency Strategy as a Risk/Reward Lever: If Ethereum appreciates in value or experiences favorable volatility, it could create unexpected gains and increased financial flexibility.
- Timing of Phase 1B Trials: The speed at which Propanc can progress from the patent grant to human trials will be a crucial catalyst. The patent enhances the significance of this timeline by protecting the therapy being tested.
- Industry Examples: Companies such as MSTR and BMNR demonstrate that cryptocurrency treasury strategies can attract investor interest and increase valuation multiples. HOTH shows that even biotech companies are beginning to embrace cryptocurrency reserve assets as part of broader treasury diversification efforts.
In Conclusion
Propanc Biopharma is navigating a challenging path: advancing innovative cancer treatments (targeting cancer stem cells and EMT modulation) while simultaneously innovating with its patent protection strategy and incorporating cryptocurrency holdings into its financing model. Its recent US patent for a clinical dose of PRP and its plans to acquire Ethereum underscore a “Curing Cancer Through Crypto” approach. The comparable companies mentioned highlight that this strategy is not without precedent and that Propanc could be next in line to succeed or attract significant attention.
Disclaimer: All opinions and information provided above are intended for educational and research purposes only. The information provided above should be used as a starting point for conducting any research on the public companies discussed. All readers should do their own due diligence and research when determining which investment strategies are best suited for them or seek the advice of an investment professional prior to making an investment decision. The profiles of the above discussed public companies are not in any way a solicitation or a recommendation to buy, sell or hold their securities. Propanc Biopharma Inc. has initiated AllPennyStocks.com for digital media advertising valued at nineteen thousand dollars. Any forward-looking statements set forth in the article above are based on expectations, estimates and projections at the time such statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “projects,” “foresees” “expects,” “will,” “anticipates,” “estimates,” “believes,” “understands” or by statements indicating certain actions “may,” “could” or “might” occur. There is no guarantee past performance will be indicative of future results or that any such forward-looking projections will occur. For a complete disclaimer, investors are encouraged to click here: https://www.allpennystocks.com/disclaimer/. PPCB IR Contact: Cavalli & Isaacs Investor Relations Richard Cavalli Phone: 303-956-1777 Email: RICHARDACAVALLI@GMAIL.COM Howard Isaacs Phone: 562-987-4939 Email: HISAACS@EARTHLINK.NET
View more of this article on AllPennyStocks.com.
About AllPennyStocks.com Media, Inc.:
Founded in 1999, AllPennyStocks.com is one of North America’s leading platforms for micro-cap insights.
Catering to both Canadian and U.S. markets, we provide a wealth of resources and expert content designed for everyone—from beginner investors to seasoned traders.
AllPennyStocks.com is rapidly gaining recognition as a leading authority in the micro-cap space, with our insightful content prominently featured across numerous top-tier financial platforms, reaching a broad audience of investors and industry professionals.
Want to showcase your company’s story to a powerful network of investors? We can help you elevate your message and make a lasting impact. Contact us today.
Contact:
AllPennyStocks.com Media, Inc.
Email: ads@allpennystocks.com
Phone: (800) 558-4560 Ext: 101